System for optical stimulation of target cells

Patent metadata

Field	Value
Publication number	US-10052497-B2
Application number	US-52252808-A
Country	US
Kind code	B2
Filing date	Jan 9, 2008
Priority date	Jul 22, 2005
Publication date	Aug 21, 2018
Grant date	Aug 21, 2018

Abstract

Stimulation of target cells using light, e.g., in vivo, is implemented using a variety of methods and devices. In one example, embodiments involve methods for stimulating target cells using a photosensitive protein that allows the target cells to be stimulated in response to light. In another specific example embodiment, target cells are stimulated using an implantable arrangement. The arrangement includes an electrical light-generation means for generating light and a biological portion. The biological portion has a photosensitive bio-molecular arrangement that responds to the generated light by stimulating target cells in vivo. Other aspects and embodiments are directed to systems and methods for screening chemicals based screening chemicals to identify their effects on cell membrane ion channels and pumps, and to systems and methods for controlling an action potential of neuron (e.g., in in vivo and in vitro environments).

First claim

What is claimed is:

1. A method for generating an inhibitory-current flow in a mammalian neuron, the method comprising:
genetically modifying a neuron to express a halorhodopsin that responds to light of a wavelength in a range of from 550 nm to 626 nm by inducing hyperpolarization of the neuron, wherein the halorhodopsin is an anion pump derived from Natromonas pharaonis.

2. The method of claim 1 , wherein the method further includes the step of genetically modifying the neuron to express an excitatory protein that responds to light by producing an excitation current to induce depolarization of the neuron.

3. The method of claim 2 , wherein the halorhodopsin has a first excitation wavelength maxima and the excitatory protein has a second excitation wavelength maxima that is different from the first excitation wavelength maxima.

4. The method of claim 3 , further including the steps of
controlling a first light source to produce a series of optical pulses each having a duration sufficient to induce individual depolarization events and
controlling a second light source to produce a series of optical pulses each having a duration sufficient to induce individual hyperpolarization events.

5. The method of claim 4 , wherein the excitatory protein includes channelrhodopsin, wherein the first light source is operated near the first excitation wavelength maxima, and wherein the second light source is operated near the second excitation wavelength maxima.

6. The method of claim 2 , wherein the inhibitory current includes chloride ions and the excitation current includes sodium ions.

7. The method of claim 1 , wherein said genetic modification-comprises introducing into the neuron a nucleic acid comprising a nucleotide sequence encoding the halorhodopsin.

8. The method of claim 1 , wherein the inhibitory current reduces depolarization of the neuron in less than 500 milliseconds after introduction of light.

9. The method of claim 1 , further including the steps of:
exposing the halorhodopsin to light to produce the inhibitory current; and
measuring a resulting ion concentration in the neuron using an optical sensor.

10. The method of claim 1 , wherein the halorhodopsin uses all-trans-retinal as a cofactor.

11. A method for controlling action potential of a neuron, the method comprising:
genetically modifying the neuron to express a first light-responsive protein;
producing, in response to light, an inhibitory current in the neuron from the first light responsive protein, wherein the first light responsive protein is a halorhodopsin that responds to light of a wavelength in a range of from 550 nm to 626 nm by inducing hyperpolarization of the neuron, and wherein the halorhodopsin is an anion pump derived from Natromonas pharaonis;
genetically modifying the neuron to express a second light-responsive protein; and
producing, in response to light, an excitation current in the neuron from the second light responsive protein.

12. The method of claim 11 , wherein the first light responsive protein has a first excitation wavelength maxima and the second light responsive protein has a second excitation wavelength maxima that is different from the first excitation wavelength maxima.

13. The method of claim 12 , further including the steps of controlling individual action potentials in an action potential train using light pulses near the first and second excitation wavelength maxima to produce the inhibitory current and the excitation current, respectively.

14. The method of claim 13 , wherein the light pulses have a frequency between 5 and 30 Hertz.

15. The method of claim 11 , wherein the steps of producing an inhibitory current and the step of producing an excitation current include implanting a light source near the neuron.

16. The method of claim 11 , wherein the first light responsive protein has a first excitation wavelength maxima and the second light responsive protein has a second excitation wavelength maxima that is different from the first excitation wavelength maxima and wherein the second light responsive protein includes channelrhodopsin.

17. The method of claim 7 , wherein the nucleic acid is a viral vector.

18. The method of claim 7 , wherein the nucleotide sequence encoding the halorhodopsin is operably linked to a neuron-specific promoter.

19. The method of claim 18 , wherein the neuron-specific promoter is a CaMKIIa promoter.

20. The method of claim 18 , wherein the neuron-specific promoter provides for expression of the halorhodopsin in cholinergic motor neurons.

21. The method of claim 2 , wherein the channelrhodopsin is ChR2.

22. The method of claim 4 , wherein the first light source and the second light source are implantable.

23. The method of claim 4 , wherein the first light source and the second light source are fiber optic light sources.

24. The method of claim 11 , wherein the light is produced by an implantable light source.

25. The method of claim 11 , wherein the light is produced by a fiber optic light source.

26. The method of claim 11 , wherein the second light-responsive protein is ChR2.

Assignees

• Deisseroth Karl
• Zhang Feng
• Mishelevich David J
• Schneider M Bret
• Univ Leland Stanford Junior

Inventors

• Deisseroth Karl
• Zhang Feng
• Mishelevich David J
• Schneider M Bret

Classifications

• A61K41/17

  by ultraviolet [UV] or infrared [IR] light, X-rays or gamma rays · CPC title

• A61N5/062

  Photodynamic therapy, i.e. excitation of an agent · CPC title

• A61N2005/0651

  Diodes · CPC title

• A61N5/0622 Primary

  Optical stimulation for exciting neural tissue · CPC title

• A61N5/0601

  Apparatus for use inside the body · CPC title